Territory Manager, Solid Tumor (Phoenix South)

Territory Manager- Solid Tumors (Phoenix South)

Reports to Regional Sales Director

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. ELZONRIS® (tagraxofusp) is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To date, Elzonris is the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

In Europe, Menarini Stemline also commercializes Nexpovio®, a first-in-class oral exportin 1 (XPO1) inhibitor for multiple myeloma in the UK, Switzerland, European Economic Area, CIS countries, Latin America and Turkey. Nexpovio is approved for use in combination with dexamethasone for treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy; and in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy. Nexpovio’s marketing authorization is valid in the EU Member States as well as Iceland, Liechtenstein, Norway, and Northern Ireland, and it has been commercially available in Germany and Austria since the fourth quarter of 2022.

In January 2023, Stemline Therapeutics, received U.S. FDA approval for ORSERDU™ (elacestrant), the first and only treatment specifically indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ESR1 mutations cause tumors to become resistant to endocrine therapy, and up to 40% of patients with ER+, HER2- mBC have tumors which harbor this mutation. ORSERDU is the first endocrine innovation in more than 20 years, and specifically addresses a major unmet need. Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumor Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB is offering in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Opportunity

Menarini Stemline is hiring a Territory Manager. Breast Cancer/Solid Tumor (Phoenix South). The Territory Manager is responsible for the sale and support of Stemline products to both existing and potential customers. The goals of this position are to acquire new customer business, increase market share through acquiring new accounts or expanding business in current customers, develop and encourage strong customer relationships, build brand loyalty, and to provide customer satisfaction.

Responsibilities

Sell products to all potential and existing customers in designated territory to achieve overall territory revenue goals.

Create strategic business plans for all key customer opportunities.

Serve as a key business partner to clients and develop and maintain strong business relationships.

Track, report and analyze territory opportunities with the Regional Sales Director (RSD) on a routine basis.

Develop relationships with hospital HCPs through conversations, meetings, participation in conferences; makes new contacts within hospital and identifies key decision makers to facilitate future orders.

Provides post-sales support of all territory business.

Responds to customer needs and complaints regarding products and/or service by developing feasible solutions or working with other related personnel (e.g. clinical, marketing, etc.) to develop optimal solutions.

Plan, prioritize, monitor, and track all sales cycle events utilizing CRM.

Monitor and report customer satisfaction, support, or issues, to the Regional Sales Director.

Monitor and update individual forecasted product volume data on a regular basis.

Responsible for meeting individual sales/business targets as provided by Management.

Attend all required Quality & Compliance training at the specified interval.

Ability to work flexible hours and weekends to meet business and/or customer needs as directed.

Participates in any and all work activities as assigned by management.

Build Compliance into all aspects of their work by maintaining compliance to all Federal and State regulatory requirements.

Skills/Knowledge

Clinical knowledge of product category with strong up to date understanding of the breast cancer treatment landscape.

Solid understanding and application of business concepts, procedures and practices.

Demonstrated ability to exceed business plan/quota, and able to develop sales plans for all required opportunities.

Capable of managing time and resources within the assigned territory in conjunction with near-term plans to ensure the territory’s objectives are achieved.

Ensure compliance with governmental and Stemline regulations. Maintaining honesty, integrity and excellent work ethic.

Able to enhance teamwork within the region and maintain a collaborative relationship with all levels of the organization.

Implement assigned operations within an established budget.

Able to influence others and function effectively in a team environment.

Excellent interpersonal, organizational, communication and listening skills.

Entrepreneurial approach to market environments.

Basic to intermediate Microsoft Office skills in Excel, Word and Outlook and CRMs.

Qualifications

Bachelor’s Degree.

Minimum of 5 years pharmaceutical/biologic experience with at least 2 years within oncology.

Breast Cancer experience preferred (ideally within past 7 years)

Proven sales track record in the relevant product line.

Must have a valid driver’s license.

While performing the functions of this position, the individual must be able to frequently sit, stand, walk and drive a vehicle for an extended period of time.

Travel is required to customer sites, including overnight travel that will vary depending on territory. Minimum expected travel is 50%+

Menarini Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Base Salary Range of $180,000-$200,000 plus incentive compensation package

Permanent Full-Time